Irinotecan

Generic Name
Irinotecan
Brand Names
Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
Drug Type
Small Molecule
Chemical Formula
C33H38N4O6
CAS Number
97682-44-5
Unique Ingredient Identifier
7673326042
Background

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy

First Posted Date
2021-08-02
Last Posted Date
2021-08-09
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Target Recruit Count
40
Registration Number
NCT04985201
Locations
🇨🇳

Shanghai pulmonary hospital, Tongji University, Shanghai, Shanghai, China

🇨🇳

CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, Shanghai, China

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

First Posted Date
2021-06-29
Last Posted Date
2022-10-05
Lead Sponsor
Agenus Inc.
Registration Number
NCT04943627
Locations
🇦🇲

Hematology Center after prof. R. Yeolyan, Yerevan, Armenia

🇦🇲

National Center of Oncology named after V.A. Fanarjian, Yerevan, Armenia

🇺🇸

Optimum Research (Southwest Women's Oncology Center), Albuquerque, New Mexico, United States

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

First Posted Date
2021-06-16
Last Posted Date
2024-08-28
Lead Sponsor
Erasmus Medical Center
Target Recruit Count
378
Registration Number
NCT04927780
Locations
🇳🇱

Amphia Hospital, Breda, Netherlands

🇳🇱

Medisch Spectrum Twente, Enschede, Netherlands

🇳🇱

Tjongerschans Hospital, Heerenveen, Netherlands

and more 19 locations

Study of CtDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

First Posted Date
2021-06-09
Last Posted Date
2024-11-06
Lead Sponsor
University of California, Irvine
Target Recruit Count
22
Registration Number
NCT04920032
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

First Posted Date
2021-05-25
Last Posted Date
2024-06-17
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
46
Registration Number
NCT04901702
Locations
🇺🇸

Lucille Packard Children's Hospital Stanford, Palo Alto, California, United States

🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

🇺🇸

Children's Healthcare of Atlanta/Emory University School of Medicine, Atlanta, Georgia, United States

and more 7 locations

RegoNivo vs Standard of Care Chemotherapy in AGOC

First Posted Date
2021-05-10
Last Posted Date
2024-05-16
Lead Sponsor
Australasian Gastro-Intestinal Trials Group
Target Recruit Count
450
Registration Number
NCT04879368
Locations
🇦🇺

Austin Health, Melbourne, Victoria, Australia

🇦🇹

Medizinische Universitaet Wien, Vienna, Austria

🇦🇹

Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria

and more 91 locations

Efficacy of Hyperthermic Intraperitoneal Chemotherapy

First Posted Date
2021-04-27
Last Posted Date
2023-12-08
Lead Sponsor
Uppsala University
Target Recruit Count
356
Registration Number
NCT04861558
Locations
🇸🇪

Sahlgrenska östra sjukhuset, Gothenburg, Sweden

🇸🇪

Skånes universitetssjukhus, Malmö, Sweden

🇸🇪

Karolinska sjukhuset, Stockholm, Sweden

and more 1 locations

c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI

First Posted Date
2021-04-06
Last Posted Date
2021-04-06
Lead Sponsor
Fudan University
Target Recruit Count
120
Registration Number
NCT04833036
Locations
🇨🇳

Fudan University Cancer Hospital, ShangHai, Shanghai, China

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

First Posted Date
2021-03-29
Last Posted Date
2024-03-13
Lead Sponsor
Flemming Forsberg
Target Recruit Count
120
Registration Number
NCT04821284
Locations
🇳🇴

Haukeland University Hospital, Bergen, Norway

🇺🇸

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

First Posted Date
2021-03-22
Last Posted Date
2024-06-14
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
7
Registration Number
NCT04808791
Locations
🇨🇦

Cross Cancer Institute, Edmonton, Alberta, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy